Clinical Trial Update: Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E [Phase 2]

View source ↗

Summary

Phase 2 study of vemurafenib (Zelboraf) in patients with locally advanced unresectable Stage IIIc or metastatic melanoma carrying activating exon 15 BRAF mutati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Zelboraf (vemurafenib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Malignant Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2017-05-25